Format

Send to

Choose Destination
Clin Pharmacol Ther. 2007 May;81(5):761-7. Epub 2007 Mar 28.

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.

Author information

1
Merck Research Laboratories, Rahway, NJ, USA.

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a new class of oral antihyperglycemic agents to treat patients with type 2 diabetes. DPP-4 inhibitors improve fasting and postprandial glycemic control without hypoglycemia or weight gain. This article focuses on the physiology, clinical pharmacology, tolerability, and clinical utility of the DPP-4 inhibitor sitagliptin in the management of type 2 diabetes.

PMID:
17392725
DOI:
10.1038/sj.clpt.6100167
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center